Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
What to Upload to SlideShare
What to Upload to SlideShare
Loading in …3
×
1 of 17

Antidiabetic drug-1

20

Share

Download to read offline

anti diabetic drug description

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Antidiabetic drug-1

  1. 1. Antidiabetic Drug  2019    ANTIDIABETIC DRUG 1 Introduction​: Anti-diabetic drug​, any ​drug​ that works to lower abnormally high ​glucose​ (​sugar​) levels in the ​blood​, which are characteristic of the ​endocrine system​ disorder known as ​diabetes mellitus​. Diabetes is caused by the body’s inability to produce or respond to the pancreatic hormone ​insulin​. One of the important physiological actions of insulin is to control blood glucose levels. Glucose is an important nutrient for cellular ​metabolism​, and ​cells​ must receive neither too little nor too much. A deficiency in the pancreatic secretion of insulin, or lack of tissue sensitivity to the hormone, leads to diabetes, the primary feature of which is elevated blood glucose levels (​hyperglycemia​). There are a number of different types of antidiabetic drug including: 1) Insulin 2) Pramlintide (Amylin) 3) GLP-1 receptor agonists (such as Byetta and Victoza) 4) Oral hypoglycemics (tablets) 2 Classification: Page 1   
  2. 2. Antidiabetic Drug  2019    2.1 Overview of Antidiabetic drug: Class Mechanism of action Side effects Contraindications Biguanide​ (​metformin​) Enhances the effect of ​insulin Lactic acidosis Weight loss Gastrointestinal complaints are common (e.g. ​diar rhea​, abdominal cramps) Reduced ​vitamin B12​absorption Chronic kidney disease Liver​ failure Metformin​ must be paused before administration of iodinated contrast medium and major surgery. Sulfonylureas​ (e.g., ​glyburid e​, glimepiride) Increase ​insulin​ secr etion from ​pancreatic​β-cel ls Risk of ​hypoglycemia Weight gain Hematological changes: ​agranulo cytosis​, ​hemolysis Severe cardiovascular comorbidity Obesity Sulfonamide​ ​allergy​ (par ticularly long-acting sub stances) Meglitinides​ (​nateglinide​, ​rep aglinide​) Increase ​insulin​ secr etion from ​pancreatic​β-cel ls Risk of ​hypoglycemia Weight gain Severe renal or ​liver​ failure DPP-4 inhibitors​ (​saxagliptin​, ​sitagli ptin​) Inhibit GLP-1 degra dation → promotes glucose-de pendent ​insulin​ secre tion Gastrointestinal complaints Pancreatitis Headache​, dizziness Arthralgia Liver​ failure Moderate to severe renal failure GLP-1 agonists​ (​incretin mimetic drugs​: ​exenatide​, ​liraglutide​, albiglutide​) Direct stimulation of the GLP-1 ​receptor Nausea Increased risk of pancreatitisand possibly ​pancreati c cancer Preexisting, symptomatic gastrointest inal motility disorders Page 2   
  3. 3. Antidiabetic Drug  2019    SGLT-2 inhibitors​(​canagliflozin​, ​dapa gliflozin​, ​empagliflozin​) Increased glucosuria through the inhibition of SGLT-2 in the kidney Genital ​yeast​ infe ctions and ​urinary tract infections Polyuria and ​dehy dration Diabetic ketoacidosis Chronic kidney disease Recurrent urinary tract infections Alpha-glucosidase inhibitors​(​acarbose​) Reduce intestinal glucose absorption Gastrointestinal complaints (flatulence, ​diarrh ea​, feeling of satiety) Any preexisting intestinal conditions (e.g., inflammatory bowel disease) Severe renal failure Thiazolidinediones​(​pioglitaz one​) Reduce insulin resistance through the stimulation of PPARs (​peroxisome proliferator-activated ​receptors​) Increase ​transcriptio n​ of adipokines Weight gain Edema Cardiac failure Increased risk of bone ​fractures​ (​os teoporosis​) Congestive heart failure Liver​ failure Amylin analogs (pramlintide) Reduce glucagon rel ease Reduce gastric emptying Increase satiety Risk of ​hypoglycemia Nausea Gastroparesis 3 Common contraindications of antidiabetic agents ● Type 1 diabetes mellitus​: Patients require ​insulin therapy​ (see principles of ​insulin therapy​). ● Pregnancy​ and breastfeeding (also see ​gestational diabetes​): All antidiabetic agents are contraindicated. Antidiabetic drugs should be substituted with human ​insulin​ as early as possible (ideally prior to the ​pregnancy​). Page 3   
  4. 4. Antidiabetic Drug  2019    ● Renal failure : Antidiabetic drugs that may be administered if ​GFR​ < 30 mL/min include DPP-4 inhibitors, ​incretin mimetic drugs​, ​meglitinides​, and ​thiazolidinediones​. ● Morbidity​ and surgery. ● Pause antidiabetic treatment in the following cases: ● Major surgery performed under general anesthesia. ● Acute conditions requiring hospitalization (infections, organ failure). ● Elective procedures associated with an increased risk of ​hypoglycemia​ (periods of fasting, irregular food intake). 4 Insulinotropic agents ● Mechanism: stimulate the secretion of ​insulin​ from ​pancreatic​ ​β-cells​. ● Glucose-independent: ​Insulin​ is secreted regardless of the blood glucose level, even if blood glucose levels are low → risk of ​hypoglycemia​. ● Sulfonylurea​, ​meglitinides​. ● Glucose-dependent: ​Insulin​ secretion is stimulated by elevated blood glucose levels (postprandially). These antidiabetic agents depend on residual ​β-cell​function. ● GLP-1 agonists, DPP-4 inhibitors.  5 Non-insulinotropic agents ● Mechanism:These agents do not depend on residual ​insulin​ production. ● Effective in patients with nonfunctional endocrine ​pancreatic​ ​β-cells​.. ● Biguanides​ (​metformin​), SGLT-2 inhibitor, ​thiazolidinediones​, alpha-glucosidase inhibitors. 5.1 Biguanides (Metformin) 5.1.1 Mechanism of action​: ● enhances the effect of ​insulin​. ● Reduction in insulin resistance via modification of glucose metabolic pathways. ● Inhibits ​mitochondrial​ glycerophosphate dehydrogenase (mGPD).. ● Decreases hepatic ​gluconeogenesis​ and intestinal glucose absorption. ● Increases peripheral ​insulin​ sensitivity. Page 4   
  5. 5. Antidiabetic Drug  2019    ● Lowers postprandial and fasting blood glucose levels. ● Reduces LDL, increases HDL. 5.1.2 Indications​:​ ​drug of choice in all patients with ​type 2 diabetes​. 5.1.3 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 1.2–2% over 3 months. ● Weight loss or weight stabilization. ● No risk of ​hypoglycemia​. ● Beneficial effect on ​dyslipidemia​. ● Studies show ​metformin​ reduces the risk of macroangiopathic complications in diabetic patients. ● Cost-effective. 5.1.4 Important side effects: ● Metformin-associated lactic acidosis. ● Incidence: ​∼​ 8 cases/100,000 patient years. ● Clinical features: frequently nonspecific. ● Gastrointestinal prodromal symptoms: nausea, vomiting, ​diarrhea​, abdominal ​pain​. ● Severe symptoms: muscle cramps, ​hyperventilation​, apathy, disorientation, ​coma​. Page 5   
  6. 6. Antidiabetic Drug  2019    ● High-risk groups. ● Elderly individuals. ● Patients with cardiac or renal insufficiency. ● Diagnostics. ● Arterial blood gas​ (​ABG​): ​metabolic acidosis​ and ​anion gap​. ● ↑ Serum ​lactate​. ● Treatment: discontinue ​metformin​ and treat acidosis. ● Gastrointestinal complaints are common: nausea, ​diarrhea​, flatulence. ● Vitamin B12 deficiency​. ● Metallic taste in the mouth (dysgeusia). 5.1.5 Contraindications: ● Renal failure (if ​creatinine clearance​ < 30 mL/min). ● Severe ​liver​ failure. ● Intravenous iodinated contrast medium. ● Pause ​metformin​ prior to surgery. ● Chronic pancreatitis​, starvation ketosis, ketoacidosis, ​sepsis​. ● Heart failure​ (​NYHA​ III and IV), respiratory failure, ​shock​, ​sepsis​. ● Alcoholism​. 5.1.6 Important interactions​:​ ​sulfonylureas 5.2 Thiazolidinediones (glitazones, insulin sensitizers) 5.2.1 Active agents: ● Pioglitazone ● Rosiglitazone 5.2.2 Mechanism of action​:  ● Activation of the ​transcription factor​ PPARγ (​peroxisome​ proliferator-activated ​receptor​ of gamma type). ● ↑ ​Transcription​ of ​genes​involved in glucose and lipid metabolism. ● ↑ levels of adipokines such as adiponectin. Page 6   
  7. 7. Antidiabetic Drug  2019    ● ↑ Storage of ​triglycerides​ and subsequent reduction of products of lipid metabolism (e.g., free ​fatty acids​) that enhance insulin resistance . ● Glucose utilization is increased and hepatic glucose production reduced. 5.2.3 Indications​:  May be considered as a monotherapy in patients with severe renal failure and/or contraindications for ​insulin therapy​. 5.2.4 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 1% in 3 months. ● Favorable effect on lipid metabolism: ↓ ​triglyceride​, ↓ LDL, ↑ HDL. ● No risk of ​hypoglycemia​.  5.2.5 Important side effects: ● Fluid retention and ​edema​. ● Weight gain. ● Increased risk of ​heart failure​. ● Increased risk of bone ​fractures​ (​osteoporosis​!). 5.2.6 Contraindications: ● Congestive heart failure​ (​NYHA​ III or IV). ● Liver​ failure. Page 7   
  8. 8. Antidiabetic Drug  2019    ● Pioglitazone​: history of ​bladder cancer​ or active ​bladder cancer​; macrohematuria of unknown origin. 5.3 Sulfonylureas 5.3.1 Active agents: ● Glyburide: the standard substance of this class with a relatively long ​half-life​. ● Glipizide: a short-acting agent. 5.3.2 Mechanism of action: ● Sulfonylureas block ​ATP​-sensitive potassium channels of the ​pancreatic​ ​β-cells​. ● Depolarization​ of ​the cell​ membrane. ● Calcium influx. ● Insulin​secretion. ● Extrapancreatic effect: decreases hepatic ​gluconeogenesis​ and increases peripheral ​insulin​ sensitivity. Page 8   
  9. 9. Antidiabetic Drug  2019    5.3.3 Indications: Particularly suitable for patients who are not overweight, do not consume alcohol, and adhere to a consistent dietary routine. 5.3.4 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 1.2% over 3 months. ● Long-term experience. ● Low-cost. 5.3.5 Important side effects: ● Life-threatening ​hypoglycemia​. ● Increased risk in patients with renal failure. ● Weight gain. ● Hematological changes: granulocytopenia, ​hemolytic anemia​. ● Allergic skin reactions. ● Alcohol intolerance. ● Compared to ​metformin​, ​sulfonylureas​ are associated with more cardiovascular (macrovascular) complications. 5.3.6 Contraindications: ● Severe cardiovascular comorbidity. ● Obesity​. ● Sulfonamide​ ​allergy​ (particularly long-acting substances). ● Severe ​liver​ failure. ● Severe kidney failure. 5.4 Meglitinides (sulfonylurea analogue) 5.4.1 Active agents: ● Repaglinide: the leading agent in the class of ​meglitinides​, which is well tolerated by patients with ​chronic kidney disease ● Nateglinide  Page 9   
  10. 10. Antidiabetic Drug  2019    5.4.2 Mechanism of action: ● Enhances ​insulin​ secretion (similar mechanism of action to that of the ​sulfonylureas​). ● Meglitinides​ should be taken shortly before meals. 5.4.3 Indications:​ particularly suitable for patients with postprandial peaks in blood glucose levels. 5.4.4 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 0.75% over 3 months. ● More expensive than ​sulfonylureas​. 5.4.5 Important side effects: ● Life-threatening ​hypoglycemia​ (less risky than ​sulfonylureas​). ● Increased risk in patients with renal failure. ● Weight gain. ● Hepatotoxicity (rare). Page 10   
  11. 11. Antidiabetic Drug  2019    5.4.6 Contraindications: ● Severe ​liver​ failure. ● Severe renal failure. 5.4.7 Interactions:​ ​Sulfonylureas​. 5.5 Incretinmimetics (GLP-1 receptor agonists) 5.5.1 Active agents: ● Exenatide. ● Liraglutide: rapid-release formula that is administered daily. ● Albiglutide: extended-release formula that is administered once weekly. ● Dulaglutide.  5.5.2 Mechanism of action: ● Incretin effect: 1. Food intake. 2. Activation of enteroendocrine cells in the ​gastrointestinal tract​. 3. Release of GLP-1. 4. GLP-1 degradation via the enzyme DPP-4. 5. End of the GLP-1 effect. ● Incretin mimetic drugs​ bind to the GLP-1 ​receptors​ and are resistant to degradation by DPP-4 enzyme ● Increase ​insulin​ secretion, decrease glucagonsecretion, slow gastric emptying (↑ feeling of satiety, ↓ weight) Page 11   
  12. 12. Antidiabetic Drug  2019    5.5.3 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 0.5–1.5% over 3 months ● Subcutaneous injection ● Weight loss ● No risk of ​hypoglycemia 5.5.4 Side effects: ● Gastrointestinal complaints (particularly impaired gastric emptying!) ● Increased risk of pancreatitis and potentially ​pancreatic cancer​ : 5.5.5 Contraindications: ● Preexisting symptomatic gastrointestinal motility disorders ● Chronic pancreatitis​ or a family history of ​pancreatic​ tumors 5.6 Dipeptidyl peptidase-4 inhibitors (gliptins) 5.6.1 Active agents: ● Sitagliptin ● Saxagliptin 5.6.2 Mechanism of action: Page 12   
  13. 13. Antidiabetic Drug  2019    ● Gliptins​ indirectly increase the endogenous incretin effect by inhibiting the dipeptidyl peptidase. ● 4 enzyme that breaks down glucagon-like peptide 1. ● Increased ​insulin​ secretion, decreased glucagon secretion, delayed gastric emptying. 5.6.3 Indications​:​  ​Antihyperglycemic therapy algorithm for type 2 diabetes​. 5.6.4 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 0.5–0.75% over 3 months.No risk of hypoglycemia unless ​insulin​ and/or insulinotropic drugs are used simultaneously. 5.6.5 Important side effects: ● Gastrointestinal complaints: ​diarrhea​, ​constipation​ (milder than in GLP-1 agonist exposure). ● Nasopharyngitis and upper respiratory tract infection. ● Arthralgia. ● Headaches, dizziness. ● Urinary infections (mild). ● Increased risk of pancreatitis. ● Acute renal failure​. Page 13   
  14. 14. Antidiabetic Drug  2019    5.6.6 Contraindications: ● Hypersensitivity. ● Liver​ failure. 5.7 SGLT-2 inhibitors (gliflozins) 5.7.1 Active agents: ● Dapagliflozin ● Empagliflozin ● Canagliflozin 5.7.2 Mechanism of action: ● Reversible inhibition of the sodium-dependent glucose co-transporter (SGLT-2) in the proximal tubule of the kidney. ● reduced glucose reabsorption in the kidney. ● glycosuria and polyuria. 5.7.3Indications:​ A treatment option used especially in young patients with treatment-compliant ​type 2 DM​ without significant renal failure. Page 14   
  15. 15. Antidiabetic Drug  2019    5.7.4 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 0.6% over 3 months. ● Promotes weight loss. ● Reduces blood pressure. 5.7.5 Important side effects: ● Urinary tract infections​, genital infections (​vulvovaginitis​, ​balanitis​). ● Dehydration​ as a result of polyuria. ● Severe ​diabetic ketoacidosis​. 5.7.6 Contraindications: ● Chronic kidney disease​. ● Recurrent urinary tract infections​ (e.g., in patients with anatomical or functional anomalies of the urinary tract). 5.8 Alpha-glucosidase inhibitors 5.8.1 Active agents: ● Acarbose ● Miglitol 5.8.2 Mechanism of action: ● Inhibits alpha-glucosidase. ● Decreased intestinal glucose absorption. ● The drug is particularly effective in controlling postprandial blood glucose levels. ● The undigested ​carbohydrates​ reach the colon, where they are degraded by intestinal bacteria, resulting in the production of intestinal gas. Page 15   
  16. 16. Antidiabetic Drug  2019    5.8.3 Clinical characteristics: ● Glycemic efficacy: lowers ​HbA1c​ by 0.8% over 3 months. ● No risk of ​hypoglycemia​. 5.8.4 Important side effects:​ gastrointestinal complaints (flatulence, abdominal discomfort, ​diarrhea​). 5.8.5 Contraindications ● Inflammatory bowel disease. ● Conditions associated with ​malabsorption​. ● Severe renal failure. Page 16   
  17. 17. Antidiabetic Drug  2019    References: 1. https://www.amboss.com/us/knowledge/Antidiabetic_drugs 2. American Diabetes Association. Diabetes Basics. Accessed 11/5/2018 3. MIMS. 2013. [12 December 2013]. Available from: ​http://www​.mims.co.uk/ Page 17   

×